SOLENO THERAPEUTICS INC short interest in 2023
In 2023, SOLENO THERAPEUTICS INC's disclosed short interest ran from 2.26% of shares outstanding on 31 Jan 2023 to 4.40% on 29 Dec 2023, a change of +2.14 percentage points. The year's high was 4.40% on 29 Dec 2023 and its low 0.76% on 28 Apr 2023, averaging 1.46% across 19 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 5.02 days on 29 Dec 2023. Full history: SOLENO THERAPEUTICS INC.
Cite this page
By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2023 in figures
- Start of year
- 2.26% (31 Jan 2023)
- End of year
- 4.40% (29 Dec 2023)
- Change
- +2.14 pp
- High
- 4.40% (29 Dec 2023)
- Low
- 0.76% (28 Apr 2023)
- Average
- 1.46%
- Highest days to cover
- 5.02 (29 Dec 2023)
- SEC filings marked
- 7
Every report in 2023
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 31 Jan 2023 | 2.26% | 1.17 | |
| 15 Feb 2023 | 1.35% | 1.30 | |
| 28 Feb 2023 | 1.34% | 3.26 | |
| 15 Mar 2023 | 1.12% | 2.12 | |
| 31 Mar 2023 | 1.04% | 3.92 | results (8-K), 10-K filed |
| 14 Apr 2023 | 1.32% | 1.29 | |
| 28 Apr 2023 | 0.76% | 1.22 | |
| 15 May 2023 | 0.87% | 1.00 | 10-Q filed, results (8-K) |
| 31 May 2023 | 1.21% | 1.00 | |
| 15 Jun 2023 | 1.10% | 1.00 | |
| 30 Jun 2023 | 0.89% | 1.02 | |
| 14 Jul 2023 | 1.01% | 2.05 | |
| 31 Jul 2023 | 0.88% | 2.56 | |
| 15 Aug 2023 | 0.82% | 2.82 | 10-Q filed, results (8-K) |
| 31 Aug 2023 | 0.80% | 1.00 | |
| 15 Nov 2023 | 1.90% | 2.33 | 10-Q filed |
| 30 Nov 2023 | 2.24% | 2.98 | |
| 15 Dec 2023 | 2.48% | 1.21 | |
| 29 Dec 2023 | 4.40% | 5.02 |
See also: SOLENO THERAPEUTICS INC's full history · most shorted US stocks of 2023 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.